Patient-factors associated with metformin steady-state levels in type 2 diabetes mellitus with therapeutic dosage
ConclusionsAlong with initial hyperglycemia and eGFR, metformin Cssmin became the only parameter that influenced FBG level (P < 0.05). Duration of previous metformin use should be considered in the strategy of optimizing metformin dosage. The type-2 diabetes patients with obesity are more suggested to take shorter interval of metformin administration (or possibly with sustained-release formulation) to keep Cssmin within the therapeutic range.
Source: Journal of Clinical and Translational Endocrinology - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fortamet | Metformin | Obesity | Study | Toxicology